Industry News

Biotechnology Industry News

As the biopharma wound down for…

January 2nd, 2026|FierceBiotech|

As the biopharma wound down for the holidays, the company reported the failure of a midphase study of BHV-7000 for the treatment of major depressive disorder.

The festive period brought some…

January 1st, 2026|FierceBiotech|

The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the companies’ respective drug applications.

Mirum Pharmaceuticals is applying…

December 23rd, 2025|FierceBiotech|

Mirum Pharmaceuticals is applying a disciplined rare disease strategy to build a high-impact portfolio. Tune in to The Top Line as Ajay Narasimha discusses pipeline momentum, strategic M&A, and how the recent Bluejay acquisition fits

Windtree Therapeutics has not been…

December 23rd, 2025|FierceBiotech|

Windtree Therapeutics has not been shy about its desire to become a revenue-generating company, even when achieving that goal means stepping outside the world of drug development. Now, the company is further divesting itself from

Despite a year of trade tensions,…

December 22nd, 2025|FierceBiotech|

Despite a year of trade tensions, national security strictures and stark warnings about the United States’ waning biotech innovation edge, the fact remains that China is and will likely continue to be a prominent source

Six people, including a former…

December 22nd, 2025|FierceBiotech|

Six people, including a former employee of investment bank Citigroup’s San Francisco office, have been charged in an alleged $41 million insider trading and stock manipulation scheme that involves two biotech companies.

Amid news of the splashy $4.8…

December 22nd, 2025|FierceBiotech|

Amid news of the splashy $4.8 billion Amicus buy, BioMarin has slipped in the discontinuation of a genetic lung disease candidate it had once hoped would become a best-in-class treatment.

Boehringer Ingelheim has opened…

December 22nd, 2025|FierceBiotech|

Boehringer Ingelheim has opened another front in its attack on chronic kidney disease, offering Rectify Pharmaceuticals up to $448 million to partner on a preclinical program.

Big Pharma-backed Aktis Oncology…

December 22nd, 2025|FierceBiotech|

Big Pharma-backed Aktis Oncology has announced plans to go public in the latest encouraging sign for those betting on a resurgence in biotech IPOs next year.

AstraZeneca has fronted $100…

December 22nd, 2025|FierceBiotech|

AstraZeneca has fronted $100 million to head deeper into the KRAS space, securing the rights to a clinical-stage, multitarget asset from China’s Jacobio Pharma.

Ipsen’s oral small molecule…

December 19th, 2025|FierceBiotech|

Ipsen’s oral small molecule failed to reduce the progression of a genetic disease that gradually turns tendons and ligaments into bone, prompting the pharma to stop the study early.

Venture capital firm Aditum Bio is…

December 19th, 2025|FierceBiotech|

Venture capital firm Aditum Bio is going all-out for a new collaboration with Fosun Pharma, launching a subsidiary with the sole purpose of developing novel therapies in tandem with the Shanghai-based drugmaker.

Merck & Co. is turning down…

December 19th, 2025|FierceBiotech|

Merck & Co. is turning down its option to license Evaxion’s gonorrhea vaccine candidate, closing the door on the Danish biotech’s chance to collect up to $592 million in biobucks.